-
UPDATE: Auriga Downgrades United Therapeutics to Hold
Thursday, August 25, 2011 - 8:20am | 89Auriga is out with its report today on United Therapeutics (NASDAQ: UTHR), downgrading UTHR to Hold from Buy. In its report, Auriga writes, "While UTHR's core franchise appears steady, the oral Remodulin combination failure complicates UTHR's regulatory and commercial outlook and removes most of...
-
UPDATE: Goldman Sachs Lowers PT on United Therapeutics to $52
Thursday, August 25, 2011 - 8:01am | 98Goldman Sachs is out with its report today on United Therapeutics (NASDAQ: UTHR), lowering its PT to $52 from $82. In its report, Goldman Sachs writes, "We are reducing our 12-month price target to $52 from $82, as we now exclude oral Remodulin from our estimates and valuation and we have also...
-
Financial Breakfast for August 25, 2011
Thursday, August 25, 2011 - 7:47am | 609This is your Benzinga news summary and traders' outlook for Thursday, August 25, 2011, covering headlines from overnight and Thursday's pre-market session. Today in domestic pre-market trading, U.S equity futures are trading slightly higher. At last check, Dow futures are up about 25 points and...
-
Benzinga's Top Downgrades
Thursday, August 25, 2011 - 7:40am | 117Collins Stewart downgraded China Sunergy Co Ltd (NASDAQ: CSUN) from “buy” to “neutral.” CSUN's shares closed at $1.23 yesterday. China Sunergy's trailing-twelve-month profit margin is 2.87%. United Therapeutics Corporation (NASDAQ: UTHR) was downgraded by Auriga from "hold" to "sell." UTHR's...
-
Auriga Downgrades United Therapeutics To Hold, $45 PT
Thursday, August 25, 2011 - 7:12am | 25Auriga has downgraded United Therapeutics (NASDAQ: UTHR) from Buy to Hold and has established a $45 price target.
-
Piper Jaffray Looks Long at Gilead Sciences
Thursday, August 25, 2011 - 7:08am | 96Piper Jaffray has published a research report on Gilead Sciences (NASDAQ: GILD). In the report, Piper Jaffray wrote, "Our call with Gilead's CEO John Martin PhD and EVP of R&D Norbert Bischofberger PhD provided insights into the HIV franchise and HCV development strategy. We are incrementally...
-
Goldman Sachs Lowers PT On United Therapeutics To $52
Thursday, August 25, 2011 - 7:02am | 27Goldman Sachs has lowered the price target on United Therapeutics (NASDAQ: UTHR) from $82 to $52 and maintains its Buy rating.
-
Pluristem's PLX Cells Receive Orphan Drug Status for Treatment of Buerger's Disease
Thursday, August 25, 2011 - 7:00am | 161Pluristem Therapeutics, Inc. (Nasdaq: PSTI) today announced that on August 22, 2011, the U.S. Food and Drug Administration (FDA) designated Pluristem's PLX cells orphan status for the treatment of thromboangiitis obliterans (Buerger's disease). The Company also announced that a concurrent...
-
Notable Put Options Activity in Momenta Pharmaceuticals
Wednesday, August 24, 2011 - 2:56pm | 82Shares of Momenta Pharmaceuticals (NASDAQ: MNTA) are higher on the session by 1.11%, currently trading at $16.39. The stock has been moving largely lower over the past three months and is currently trading below the 50-day moving average. Options traders are focusing on puts today. A short while...
-
Investor FAQs and Facts for BioSante Pharmaceuticals, Inc
Wednesday, August 24, 2011 - 12:27pm | 1579POINT ROBERTS, August 24, 2001 - www.InvestorIdeas.com, a global investor research portal for independent investors features an investor FAQ and Fact Sheet for specialty pharmaceutical company, BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX). BioSante's (NASDAQ: BPAX) stock has built a significant...
-
McNicoll, Lewis & Vlak Maintains Peregrine Pharmaceuticals Buy, PT
Wednesday, August 24, 2011 - 12:07pm | 144McNicoll, Lewis & Vlak maintained its Peregrine Pharmaceuticals (NASDAQ: PPHM) Buy rating and $8.50 price target in a research report published today. In the report, McNicoll, Lewis & Vlak states, "Currently, Peregrine is conducting three randomized Phase II trials of Bavi in combination...
-
Morning Market Losers
Wednesday, August 24, 2011 - 9:51am | 94Pacific Sunwear of California Inc (NASDAQ: PSUN) fell 38.25% to $1.34 at 9:50 am. PSUN issued downbeat Q3 forecast. Inphi Corporation (NYSE: IPHI) shares lost 27.52% to $7.61. IPHI lowered its second-half forecast. United Therapeutics Corporation (NASDAQ: UTHR) shares dipped 18.15% to $39.91....
-
Morning Market Movers
Wednesday, August 24, 2011 - 9:46am | 101Peoples Educational Holdings Inc (NASDAQ: PEDH) climbed 31.82% to $1.45 at 9:45 am. PEDH shares have surged 25.00% over the past 52 weeks, while the S&P 500 index has gained 10.50% in the same period. Peregrine Pharmaceuticals Inc (NASDAQ: PPHM) shares advanced 25.95% to $1.65. PPHM announced...
-
UPDATE: Wunderlich Initiates Coverage on Edwards Lifesciences
Wednesday, August 24, 2011 - 9:45am | 112Wunderlich has published a research report on Edwards Lifesciences (NASDAQ: UTHR) initiating coverage of the thing. In the report, Wunderlich wrote, "EW has been one of the premier growth stocks in the MedTech sector in recent years, driven by international success of the company's SAPIEN...
-
UPDATE: J.P. Morgan Downgrades United Therapeutics to Neutral
Wednesday, August 24, 2011 - 9:28am | 87J.P. Morgan is out with its report today on United Therapeutics (NASDAQ: UTHR), downgrading UTHR to Neutral from Overweight. In its report, J.P. Morgan writes, "In the meantime, we wouldn't expect the Street to be comfortable with upside drivers beyond oral, and, as such, we're downgrading UTHR...